J&J agrees $14.6bn takeover of CNS biotech Intra-Cellular

Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.

Intra-Cellular sets up $500m offer on Caplyta depression win

Shares in Intra-Cellular Therapies rose sharply after it reported that its only product Caplyta was effective for a new indication, major depressive disorder (MDD), in a p

Aduhelm approval could signal new era for CNS drugs; analyst...

The unexpected approval and lofty pricing of Biogen's Alzheimer's therapy Aduhelm is clearly the biopharma event of the year so far, but what are the broader implications for the industry a

Intra-Cellular ends year with OK for schizophrenia drug luma...